<div id="readability-page-1"><p>In a report released yesterday,  from Guggenheim maintained a Buy rating on Centessa Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$43.00</span>. The company’s shares closed yesterday at $27.32.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul>  <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Centessa Pharmaceuticals with a $37.10 average price target, implying a 35.80% upside from current levels. In a report released on November 13, Wells Fargo also maintained a Buy rating on the stock with a $35.00 price target.</p></div>

CNTA

<p>Guggenheim maintains a Buy rating on Centessa Pharmaceuticals with a $43.00 price target. The stock closed at $27.32, with a Strong Buy consensus and a $37.10 average price target, indicating a 35.80% upside. Wells Fargo also maintains a Buy rating with a $35.00 target.</p>

Centessa Pharmaceuticals (CNTA) Gets a Buy from Guggenheim